(Adnkronos) - “Novartis investe ogni anno in ricerca e sviluppo circa 60 milioni di euro con un numero di studi clinici pari a circa 200 ogni anno. Nell'area cardiovascolare è importante il nostro contributo nella ricerca di quei fattori di rischio che concorrono alle patologie che rappresentano, a oggi, una delle principali cause di morte e di morbidità, anche grazie alle nuove scoperte, come per esempio gli alti livelli di lipoproteina-a e l'individuazione di nuovi fattori di rischio che in qualche modo concorrono poi alla genesi delle patologie cardiovascolari”. Lo ha dichiarato Paola Coco, Chief Scientific Officer and Medical affairs head Novartis, intervenendo all'evento ‘Voices for Silencing’ organizzato, il 7-8 marzo a Milano proprio da Novartis, per offrire ai cardiologi un aggiornamento scientifico sulla gestione ottimale del paziente con ipercolesterolemia.
Category
🗞
NewsTranscript
00:00Novartis has decided to focus on four fundamental therapeutic areas,
00:12which are the cardiovascular area, the oncological area, the neuroscience area and the immunology area.
00:19In these four areas, we are looking, through innovative technological platforms
00:25that are next to the more conventional platforms,
00:29to identify treatments that are increasingly personalized for the patient.
00:36In particular, cellular therapies, hygienic therapies, RNA-based therapies and radiology therapies.
00:45In the future, our commitment will certainly continue,
00:50in particular in the cardiovascular area,
00:53it is important our contribution in the research of those cardiovascular risk factors
00:59that compete with the pathologies that today represent one of the main causes of death and morbidity.
01:07And also thanks to the new discoveries, such as the high levels of lipoprotein A,
01:14the identification of new risk factors that somehow compete with the genesis of these cardiovascular pathologies.
01:23We have also recently had important acquisitions from other companies
01:28and therefore the idea is precisely to expand the leadership in the cardiovascular area
01:33also on other pathologies, such as, for example,
01:36the prevention of diffuse embolism and ictus in patients with atrial fibrillation.
01:43Novartis is the first research and development company in Italy
01:49with an annual investment of about 60 million euros
01:54and a number of clinical studies equal to about 200 every year.